New Delhi: The Central Government has restricted the manufacturing, sale and distribution of fixed-dose combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for children below four years of age, citing potential health risks associated with the use of these medicines in young children.
The Ministry of Health and Family Welfare issued a notification directing manufacturers to prominently display a warning on the labels, package inserts and promotional material associated with such formulations. The mandatory warning states that the fixed-dose combination shall not be used in children below four years of age.
The move is aimed at strengthening safeguards for young children and ensuring that parents, caregivers, healthcare professionals and other consumers are clearly informed about the age restriction before these medicines are used.
Chlorpheniramine Maleate is an antihistamine commonly used to relieve symptoms associated with allergies and cold-related conditions, while Phenylephrine Hydrochloride is a decongestant used to help relieve nasal congestion. The two ingredients are available together in several fixed-dose formulations used for symptoms such as a blocked or runny nose.
However, the government has now specifically restricted the use of combinations containing these two ingredients in children below four years, stating that such formulations may pose risks to young children and that safer alternatives are available.
Under the new direction, manufacturers are required to ensure that the warning is clearly visible across all relevant forms of communication associated with the medicines. This includes the product label, package insert and promotional literature.
The warning is intended to prevent accidental or inappropriate administration of these formulations to children below the specified age. By making the restriction mandatory on packaging and promotional material, authorities are seeking to ensure that the information reaches consumers at the point where medicines are purchased or administered.
The decision follows recommendations made by an Expert Committee and the Drug Technical Advisory Board (DTAB), which examined the safety and appropriate use of the fixed-dose combinations.
The latest restriction is part of a broader effort by the government to review the safety and rational use of fixed-dose combination medicines. FDCs contain two or more active pharmaceutical ingredients in a single formulation and are widely used for treating various conditions.
While such combinations can provide convenience in certain circumstances, regulators have also raised concerns over the safety and appropriateness of some FDCs, particularly when their ingredients may not be suitable for specific age groups or medical conditions.
The government has therefore been reviewing medicines based on expert recommendations and regulatory assessments. The latest action specifically focuses on the use of Chlorpheniramine Maleate and Phenylephrine Hydrochloride combinations among children below four years.
The restriction is particularly significant because young children can respond differently to medicines compared with older children and adults. Their bodies are still developing, and medicines that may be considered appropriate for older age groups may carry different risks when administered to very young children.
The government has accordingly emphasised the availability of safer alternatives for children below four years. Parents and caregivers are expected to consult qualified healthcare professionals before giving medicines to young children, particularly for symptoms associated with cold, cough, allergy or nasal congestion.
The notification also places responsibility on pharmaceutical manufacturers to comply with the new labelling requirements. Companies producing the affected formulations will have to ensure that the prescribed warning appears clearly on all applicable packaging and accompanying information.
Promotional material for these products will also have to carry the required warning. This is intended to prevent marketing or advertising material from creating confusion about the appropriate age group for the medicines.
The latest decision comes after the Ministry of Health and Family Welfare prohibited the manufacturing, sale and distribution of 16 fixed-dose combination drugs for human use across the country in June this year.
That earlier action was also taken following recommendations from the Expert Committee and the Drug Technical Advisory Board. It reflected the government’s continuing review of pharmaceutical formulations and its efforts to ensure that medicines available in the Indian market meet appropriate safety and regulatory standards.
The restrictions on FDCs form part of the government’s broader approach towards rationalising medicines and protecting consumers from formulations that may present unnecessary risks or lack sufficient justification for particular uses.
The latest notification does not mean that every medicine containing either Chlorpheniramine Maleate or Phenylephrine Hydrochloride individually has been prohibited. Instead, the specific concern addressed by the notification relates to fixed-dose combinations containing the two ingredients for children below four years of age.
The distinction is important because the government has imposed an age-specific restriction rather than announcing a blanket prohibition on the individual medicines across all age groups.
Healthcare professionals and pharmaceutical companies are expected to take note of the new requirement and ensure compliance. The mandatory warning will also help pharmacists and consumers identify the formulations that carry the restriction.
The government has said that the measure has been introduced as a significant step towards protecting the health and safety of young children. Authorities have emphasised that the availability of safer alternatives is one of the reasons for restricting the use of these combinations in children below four.
For parents, the development serves as a reminder that medicines intended for adults or older children should not automatically be given to infants and very young children. Even commonly used medicines for cold and allergy symptoms can require careful consideration based on age, dosage and medical circumstances.
The restriction also highlights the importance of avoiding self-medication in young children. Parents and caregivers may sometimes rely on over-the-counter medicines for common symptoms such as a runny nose or congestion, but the latest government directive reinforces the need to pay attention to age-specific safety information.
The pharmaceutical industry will now have to ensure that affected products comply with the prescribed warning requirements. Failure to follow regulatory directions could invite action under applicable drug laws and regulations.
The government’s latest decision is therefore significant both from a public-health perspective and from a pharmaceutical regulatory standpoint. By specifically identifying children below four years as a vulnerable age group, authorities have sought to reduce the possibility of inappropriate use of these fixed-dose combinations.
As the new restrictions take effect, healthcare professionals, pharmacists, manufacturers and consumers will need to ensure that the age-related warning is properly understood and followed.
The move forms part of the government’s continuing efforts to strengthen medicine safety in India and ensure that pharmaceutical formulations are used appropriately, particularly among vulnerable groups such as young children.
With the mandatory warning now required on labels, package inserts and promotional material, the government expects greater awareness among consumers and healthcare providers and a reduction in the inappropriate use of Chlorpheniramine Maleate and Phenylephrine Hydrochloride combinations among children below four years.
Read More: FSSAI Suspends Dior Pharmaceuticals Licence After Finding Major Food Safety Violations at Punjab Nutraceutical Unit
Follow for more updates: www.instagram.com/imnindia.news
Leave a comment